Comparison of a new WBC-reduction system and the standard plateletpheresis protocol in the same donors

Transfusion

Volumn 41, Issue 3, 2001, Pages 396-400

  Zingsem, Jürgen ^a,b   Zimmermann, Robert ^a,b   Weisbach, Volker ^a,b   Glaser, Anke ^a,b   Bunkens, Helena ^a,b   Eckstein, Reinhold ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Gambro BCT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD DONOR; CELL SEPARATION; CLINICAL ARTICLE; HUMAN; LEUKOCYTE; RELIABILITY; THROMBOCYTE COUNT; THROMBOCYTOPHERESIS;

BLOOD DONORS; HUMANS; LEUKAPHERESIS; PLATELETPHERESIS;

EID: 0035084535     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41030396.x     Document Type: Article

References (42)

1. The role of transfusions in postoperative cytomegalovirus infections (in nonimmunosuppressed subjects)
2. Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection
3. Transfusion-acquired cytomegalovirus infection in neonates. A prospective study
4. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes
5. Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization
6. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: Transfusion of blood products
7. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension
8. Alloimmunization to HLA antigens following transfusion with leucocyte poor and purified platelet suspensions
9. Development of lymphocytotoxic and platelet reactive antibodies: A prospective study in patients with acute leukaemia
10. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer
11. Relative importance of immune and non-immune causes of platelet refractoriness
12. Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters
13. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components
14. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
15. Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia
16. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
17. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened bloodbank donors
18. Reducing white cells in platelet units
19. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial
20. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
21. Filtration. A method to prepare white cell-poor platelet concentrates with optimal preservation of platelet viability
22. Leukocyte depletion and storage of single-donor platelet concentrates
23. Platelet concentrates stored in synthetic medium after filtration
24. Transfusion results of filtered and subsequently stored random platelet suspensions prepared from buffy coats
25. Changes in thrombocytapheresis concentrates caused by leukocyte depletion with polyester filters
26. Effect of filtration on subsequently stored platelet concentrates
27. White cell reduction in platelet concentrates and packed red cells by filtration: A multicenter clinical trial
28. Effect of in vitro storage time of platelet concentrates on clogging of white cell-reduction filters
29. Significantly lower platelet loss by filtering Spectra apheresis platelets on day 0 with a rest versus day 1 without a rest
30. White cell depletion of red cell and random-donor platelet concentrates by filtration and residual lymphocyte subset analysis
31. A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets
32. Comparison of COBE white cell-reduction and standard plateletpheresis protocols in the same donors
33. Evaluation of a platelet apheresis technique for the preparation of leukocyte-reduced platelet concentrates
34. Preparative cell apheresis for the collection of blood components: Recommendations from the Permanent Hemapheresis Commission of the German Society for Transfusion Medicine and Immunohematology
35. Large-volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC-reduced platelets: Validation and application for quality control of WBC-reduced platelets prepared by apheresis and filtration
36. Validation of use of the Nageotte hemocytometer to count low levels of white cells in white cell-reduced platelet components
37. Practical guidelines for process validation and process control of white cell-reduced blood components: Report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)
38. In vitro and in vivo effects of prestorage filtration of apheresis platelets
39. Periodic alternating interface positioning to lower WBC contamination of apheresis platelet concentrates: A multicenter evaluation
40. Prospective comparison of plateletapheresis using four apheresis systems on the same donors